EUCTR2009-016827-72-SE进行中（未招募）不适用
A multicentre, randomized, double-blind, safety and efficacy non-inferiority, intra-individual study, comparing Mometasone furoate Galenica 0.1% cream with Elocon 0.1% cream and placebo in patients with mild to moderate plaque psoriasis.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Galenica AB
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Patient must voluntarily give written informed consent.
- •-Men or women 18 years old or above.
- •-Diagnosis of mild to moderate stable plaque proriasis (PASI score <10).
- •-Four psoriasis lesions (2x2 symetrically placed lesions) on the arms or the legs. Each lesion must be at least 3 cm in diameter and TSS sum score of at least 5.
- •-Females of childbearing potential (includes women who are less than one year menopausal) and must have a negative urine pregnancy test.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patient has neglected the wash-out period of other psoriasis treatments on the lesions to be studied.
- •-Any other form of psoriasis other than plaque psoriasis or non-treated mild psoriasis arthritis.
- •-Any other active skin disease, other dermatological condition or bacterial, viral, fungal skin infection.
- •-Treatment with systemic or locally acting medications, which might counter or influence the study aims, within 2 weeks before the beginning of the study.
研究者
相似试验
已完成
不适用
Tenelia Triple Combination StudyEndocrine, nutritional and metabolic diseaseKCT0001919Handok200
进行中（未招募）
不适用
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors - NDHaemophilia A with antifactor VIII and Haemophilia B with antifactor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIEUCTR2006-004879-35-ITOVO NORDISK50
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-FRovo Nordisk A/S
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-HUovo Nordisk A/S
进行中（未招募）
1 期
A multi-centre, randomised, double-blinded, controlled, dose-escalation trial on safety and efficacy of activated recombinant FVII analogue (NN1731) in the treatment of joint bleeds in congenital haemophilia patients with inhibitors.Trial phase: 2Haemophilia A with anti factor VIII and Haemophilia B with anti factor IXMedDRA version: 9.1Level: LLTClassification code 10056492Term: Haemophilia A with anti factor VIIIMedDRA version: 9.1Level: LLTClassification code 10056494Term: Haemophilia B with anti factor IXEUCTR2006-004879-35-GBovo Nordisk A/S70